Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Canada Aims To Educate On Biosimilars

New Campaign Kicks Off This Week

Executive Summary

A dedicated website will spearhead a public education campaign initiated by Sandoz Canada for biosimilars, as their influence and presence continue to grow in the North American market. Sandoz itself is planning a portfolio of five products by the middle of 2021.

You may also be interested in...



Sandoz’ Ziextenzo And Riximyo Cleared In Canada

Sandoz Canada is looking to bolster its portfolio of biosimilars after obtaining marketing authorizations for both pegfilgrastim and rituximab.

Alberta Is Second Canadian Province To Switch To Biosimilars

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Samsung Bioepis Added To Avastin Biosimilar Litigants

Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel